查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574062

醫藥品受託製造的全球市場:2024-2034年

Pharmaceutical Contract Manufacturing Market Report 2024-2034
出版日期: | 出版商: Visiongain | 英文 349 Pages | 商品交期: 最快1-2個工作天內

價格

到 2034 年，全球藥品合約製造市場預計將以 11.5% 的複合年增長率成長。

內部藥物開發成本高

內部藥物開發和製造成本的上升正在推動藥品合約製造市場的顯著成長。一種新藥從發現到上市的開發過程可能超過 20 億美元，歷時超過 10 年。由於需要大量資金，製藥公司被迫將生產外包給 CDMO（合約藥物開發和製造組織）。 CDMO 可以透過規模經濟和專業知識來實現成本效率。

Thermo Fisher Scientific 和 Samsung Biologics 等公司正在擴大其合約製造能力，以滿足製藥公司不斷增長的降低營運成本的需求。這些 CDMO 使製藥公司能夠透過提供從早期開發到商業規模生產的全面端到端服務來降低內部成本。

此外，研發成本上升、監管力度加大以及市場競爭加劇帶來的財務壓力正迫使製藥公司尋求更具成本效益的解決方案。透過外包給 CDMO，製藥公司可以更具策略性地分配資源，專注於創新和市場擴張，同時依靠合約製造商進行高效和可擴展的生產。

法規要求因地區而異

遵守監管指南並維持高品質標準是製藥業面臨的嚴峻挑戰。藥品品質不合規或不合格會對業務運營和品牌聲譽產生嚴重影響。在合約藥物開發和製造組織（CDMO）領域，合約生產的藥品以合約公司的品牌名稱進行銷售，必須嚴格遵守監管要求。

本報告提供全球醫藥品受託製造的市場調查，彙整市場概要，影響市場成長因素及市場機會分析，市場規模的轉變·預測，各種區分·地區/各主要國家的詳細分析，競爭情形，主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 摘要整理

第3章 市場概要

  • 主要調查結果
  • 市場動態
  • 影響分析
    • 市場推動要素
    • 阻礙市場要素
    • 市場機會
  • 法律規範
  • 新興市場與大趨勢
  • 波特的五力分析
  • PEST分析
  • SWOT分析

第4章 醫藥品受託製造市場分析:各類服務

  • 主要調查結果
  • 市場魅力指數
  • 市場規模的轉變·預測
  • 醫藥品製造服務
  • 醫藥品開發服務
  • 生物醫藥品製造服務
    • 市場規模的轉變·預測:各地區
    • 市場佔有率:各地區

第5章 醫藥品受託製造市場分析:各醫藥品類型

  • 主要調查結果
  • 市場魅力指數
  • 市場規模的轉變·預測
  • 品牌
  • 非專利
    • 市場規模的轉變·預測:各地區
    • 市場佔有率:各地區

第6章 醫藥品受託製造市場分析:各終端用戶

  • 主要調查結果
  • 市場魅力指數
  • 市場規模的轉變·預測
  • 大型製藥公司
  • 中小製藥企業
  • 學名藥公司
  • 其他
    • 市場規模的轉變·預測:各地區
    • 市場佔有率:各地區

第7章 醫藥品受託製造市場分析:各產業規模

  • 主要調查結果
  • 市場魅力指數
  • 市場規模的轉變·預測
  • 臨床
  • 商業
    • 市場規模的轉變·預測:各地區
    • 市場佔有率:各地區

第8章 醫藥品受託製造市場分析:各地區

  • 主要調查結果
  • 市場規模的轉變·預測

第9章 北美的醫藥品受託製造市場分析

第10章 歐洲的醫藥品受託製造市場分析

第11章 亞太地區的醫藥品受託製造市場分析

第12章 南美的醫藥品受託製造市場分析

第13章 中東·非洲的醫藥品受託製造市場分析

第14章 企業簡介

  • 競爭情形
  • Lonza
  • Catalent, Inc.
  • Recipharm AB
  • AbbVie Inc.
  • Thermo Fisher Scientific Inc.
  • Siegfried Holding AG
  • Evonik Industries AG
  • Boehringer Ingelheim International GmbH
  • Piramal Pharma Solutions
  • Samsung Biologics
  • WuXi AppTec
  • FUJIFILM Diosynth Biotechnologies
  • ICON plc
  • Abnova Corporation
  • Vetter Pharma
  • Aenova Group
  • Almac Group
  • Nipro Pharma Corporation
  • Jubilant Pharmova Limited
  • Pfizer Inc.
  • Grifols, S.A.
  • Charles River Laboratories
  • IQVIA Inc.
  • Baxter
  • Curia Global, Inc.
  • Lannett

第15章 總論·建議

  • Visiongain的總論
  • 市場參與企業的建議
Product Code: PHA1348

The global Pharmaceutical Contract Manufacturing market is projected to grow at a CAGR of 11.5% by 2034

The Pharmaceutical Contract Manufacturing Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

High Cost of In-house Drug Development

The rising costs associated with in-house drug development and manufacturing are driving significant growth in the pharmaceutical contract manufacturing market. The process of developing a new drug, from discovery to market launch, can exceed $2 billion and span over a decade. These substantial financial requirements are compelling pharmaceutical companies to outsource their manufacturing needs to Contract Development and Manufacturing Organizations (CDMOs), which provide cost efficiencies through economies of scale and specialized expertise.

Companies such as Thermo Fisher Scientific and Samsung Biologics are expanding their contract manufacturing capabilities to meet the growing demand from pharmaceutical firms seeking to reduce operational costs. These CDMOs offer comprehensive end-to-end services, ranging from early-stage development to commercial-scale manufacturing, thereby enabling pharmaceutical companies to lower their in-house expenditures.

In addition, the financial pressures resulting from escalating R&D costs, increased regulatory scrutiny, and heightened market competition are driving pharmaceutical companies to seek more cost-effective solutions. Outsourcing to CDMOs allows these companies to allocate their resources more strategically, focusing on innovation and market expansion while relying on contract manufacturers for efficient and scalable production.

Varying Regulatory Requirements Across Regions

Ensuring compliance with regulatory guidelines and maintaining high-quality standards are critical imperatives for the pharmaceutical industry, as noncompliance and substandard drug quality can have severe repercussions for both business operations and brand reputation. In the realm of Contract Development and Manufacturing Organizations (CDMOs), the drugs produced under contract are marketed under the brand name of the contractor, necessitating meticulous adherence to regulatory requirements.

The drug development process involves extensive data collection and submission to regulatory authorities throughout various stages, including development and clinical trials. For CDMOs, managing and submitting this data across multiple formulations and jurisdictions poses significant challenges. The complexity of handling diverse regulatory submissions and the potential for errors in regulatory filings can impede the efficiency and effectiveness of CDMOs.

These regulatory and quality control challenges are likely to impact the growth trajectory of the pharmaceutical CDMO market in the forthcoming years. As the industry continues to evolve, CDMOs must navigate the complexities of regulatory compliance while striving to maintain high-quality manufacturing standards to mitigate risks and sustain market growth.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the pharmaceutical contract manufacturing market evolving?
  • What is driving and restraining the pharmaceutical contract manufacturing market?
  • How will each pharmaceutical contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each pharmaceutical contract manufacturing submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading pharmaceutical contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the pharmaceutical contract manufacturing projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of
  • pharmaceutical contract manufacturing projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing market?
  • Where is the pharmaceutical contract manufacturing market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the pharmaceutical contract manufacturing market today, and over the next 10 years:

  • Our 349-page report provides 143 tables and 198 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them , NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2034 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Services
  • Pharmaceutical Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services
  • Drug Type
  • Branded
  • Generics
  • End-users
  • Big Pharmaceutical Companies
  • Small & Medium-sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies
  • Other End-users
  • Scale of Operation
  • Clinical
  • Commercial

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 28 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Switzerland
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Malaysia
  • Singapore
  • Indonesia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Pharmaceutical Contract Manufacturing Market, 2024 to 2034, with a focus on this segment of these companies' operations.

  • Leading companies profiled in the report
  • AbbVie Inc.
  • Abnova Corporation
  • Aenova Group
  • Almac Group
  • Baxter
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Charles River Laboratories
  • Curia Global, Inc.
  • Evonik Industries AG
  • FUJIFILM Diosynth Biotechnologies
  • Grifols, S.A.
  • ICON plc
  • IQVIA Inc.
  • Jubilant Pharmova Limited
  • Lannett
  • Lonza
  • Nipro Pharma Corporation
  • Piramal Pharma Solutions
  • Pfizer Inc.
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma
  • WuXi AppTec

Overall world revenue for Pharmaceutical Contract Manufacturing Market, 2024 to 2034 in terms of value the market will surpass US$155 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Pharmaceutical Contract Manufacturing Market, 2024 to 2034 report help you?
  • In summary, our 340+ page report provides you with the following knowledge:
  • Revenue forecasts to 2034 for Pharmaceutical Contract Manufacturing Market 2024 to 2034, with forecasts for services, drug type, end-users, and scale of operation, each forecast at a global and regional level , discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 28 key national markets , See forecasts for the Pharmaceutical Contract Manufacturing Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market , including company profiles for 26 of the major companies involved in the Pharmaceutical Contract Manufacturing Market, 2024 to 2034.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
  • Information found nowhere else
  • With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Pharmaceutical Contract Manufacturing Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Pharmaceutical Contract Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Patent Expiry and Increasing Demand for Generic Drugs
      • 3.3.1.2 Increasing Investments in Pharmaceutical R&D
      • 3.3.1.3 Investments in Advanced Manufacturing Technologies by CDMOs
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Introduction of Serialization
      • 3.3.2.2 Varying Regulatory Scenarios
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Increasing Demand for Biological Therapies
      • 3.3.3.2 Growth in the Nuclear Medicine Sector
      • 3.3.3.3 Growing Demand for Cell and Gene Therapies
  • 3.4 Regulatory Framework
  • 3.5 Emerging Markets and Megatrends
  • 3.6 Porter's Five Forces Analysis
    • 3.6.1 Bargaining Power of Supplier
    • 3.6.2 Bargaining Power of Buyer
    • 3.6.3 Threat of New Entrants
    • 3.6.4 Threat of Substitutes
    • 3.6.5 Competitive Rivalry
  • 3.7 PEST Analysis
  • 3.8 SWOT Analysis

4 Pharmaceutical Contract Manufacturing Market Analysis by Services

  • 4.1 Key Findings
  • 4.2 Services Segment: Market Attractiveness Index
  • 4.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 4.4 Pharmaceutical Manufacturing Services
    • 4.4.1 Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
    • 4.4.2 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 4.4.3 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Drug Development Services
    • 4.5.1 Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
    • 4.5.2 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 4.5.3 Market Share by Region, 2024 & 2034 (%)
  • 4.6 Biologics Manufacturing Services
    • 4.6.1 Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
    • 4.6.2 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 4.6.3 Market Share by Region, 2024 & 2034 (%)

5 Pharmaceutical Contract Manufacturing Market Analysis by Drug Type

  • 5.1 Key Findings
  • 5.2 Drug Type Segment: Market Attractiveness Index
  • 5.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 5.4 Branded
    • 5.4.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Generics
    • 5.5.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)

6 Pharmaceutical Contract Manufacturing Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 6.4 Big Pharmaceutical Companies
    • 6.4.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Small & Medium-sized Pharmaceutical Companies
    • 6.5.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Generic Pharmaceutical Companies
    • 6.6.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 Other End-users
    • 6.7.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 Pharmaceutical Contract Manufacturing Market Analysis by Scale of Operation

  • 7.1 Key Findings
  • 7.2 Scale of Operation Segment: Market Attractiveness Index
  • 7.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 7.4 Clinical
    • 7.4.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Commercial
    • 7.5.1 Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 Pharmaceutical Contract Manufacturing Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Pharmaceutical Contract Manufacturing Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • 9.3 North America Pharmaceutical Contract Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 9.4 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
  • 9.5 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 9.6 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 9.7 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 9.8 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 9.9 U.S. Pharmaceutical Contract Manufacturing Market Analysis
  • 9.10 Canada Pharmaceutical Contract Manufacturing Market Analysis

10 Europe Pharmaceutical Contract Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • 10.3 Europe Pharmaceutical Contract Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 10.4 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 10.6 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 10.7 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 10.8 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 10.9 Germany Pharmaceutical Contract Manufacturing Market Analysis
  • 10.10 UK Pharmaceutical Contract Manufacturing Market Analysis
  • 10.11 France Pharmaceutical Contract Manufacturing Market Analysis
  • 10.12 Italy Pharmaceutical Contract Manufacturing Market Analysis
  • 10.13 Spain Pharmaceutical Contract Manufacturing Market Analysis
  • 10.14 Russia Pharmaceutical Contract Manufacturing Market Analysis
  • 10.15 Switzerland Pharmaceutical Contract Manufacturing Market Analysis
  • 10.16 Netherlands Pharmaceutical Contract Manufacturing Market Analysis
  • 10.17 Rest of Europe Pharmaceutical Contract Manufacturing Market Analysis

11 Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • 11.3 Asia Pacific Pharmaceutical Contract Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 11.6 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 11.7 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 11.8 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 11.9 Japan Pharmaceutical Contract Manufacturing Market Analysis
  • 11.10 China Pharmaceutical Contract Manufacturing Market Analysis
  • 11.11 India Pharmaceutical Contract Manufacturing Market Analysis
  • 11.12 Australia Pharmaceutical Contract Manufacturing Market Analysis
  • 11.13 South Korea Pharmaceutical Contract Manufacturing Market Analysis
  • 11.14 Malaysia Contract Manufacturing Market Analysis
  • 11.15 Singapore Pharmaceutical Contract Manufacturing Market Analysis
  • 11.16 Indonesia Pharmaceutical Contract Manufacturing Market Analysis
  • 11.17 Rest of Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis

12 Latin America Pharmaceutical Contract Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • 12.3 Latin America Pharmaceutical Contract Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 12.6 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 12.7 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 12.8 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 12.9 Brazil Pharmaceutical Contract Manufacturing Market Analysis
  • 12.10 Mexico Pharmaceutical Contract Manufacturing Market Analysis
  • 12.11 Argentina Pharmaceutical Contract Manufacturing Market Analysis
  • 12.12 Colombia Pharmaceutical Contract Manufacturing Market Analysis
  • 12.13 Rest of Latin America Pharmaceutical Contract Manufacturing Market Analysis

13 MEA Pharmaceutical Contract Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • 13.3 MEA Pharmaceutical Contract Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
  • 13.6 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
  • 13.7 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
  • 13.8 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 13.9 GCC Pharmaceutical Contract Manufacturing Market Analysis
  • 13.10 South Africa Pharmaceutical Contract Manufacturing Market Analysis
  • 13.11 Rest of MEA Pharmaceutical Contract Manufacturing Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape
  • 14.2 Lonza
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
      • 14.2.3.1 Net Revenue, 2018-2023
      • 14.2.3.2 R&D, 2018-2023
      • 14.2.3.3 Regional Market Shares, 2023
      • 14.2.3.4 Business Segment Market Shares, 2023
    • 14.2.4 Service Benchmarking
    • 14.2.5 Strategic Outlook
    • 14.2.6 SWOT Analysis
  • 14.3 Catalent, Inc.
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2018-2023
      • 14.3.3.2 Regional Market Shares, 2023
      • 14.3.3.3 Business Segment Market Shares, 2023
    • 14.3.4 Service Benchmarking
    • 14.3.5 Strategic Outlook
    • 14.3.6 SWOT Analysis
  • 14.4 Recipharm AB
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Service Benchmarking
    • 14.4.4 Strategic Outlook
    • 14.4.5 SWOT Analysis
  • 14.5 AbbVie Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2018-2023
      • 14.5.3.2 R&D, 2018-2023
      • 14.5.3.3 Regional Market Shares, 2023
      • 14.5.3.4 Business Segment Market Shares, 2023
    • 14.5.4 Service Benchmarking
    • 14.5.5 SWOT Analysis
  • 14.6 Thermo Fisher Scientific Inc.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2018-2023
      • 14.6.3.2 R&D, 2018-2023
      • 14.6.3.3 Regional Market Shares, 2023
      • 14.6.3.4 Business Segment Market Shares, 2023
    • 14.6.4 Service Benchmarking
    • 14.6.5 Strategic Outlook
    • 14.6.6 SWOT Analysis
  • 14.7 Siegfried Holding AG
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2018-2023
      • 14.7.3.2 Business Segment Market Shares, 2023
    • 14.7.4 Service Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Evonik Industries AG
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
      • 14.8.3.1 Net Revenue, 2018-2023
      • 14.8.3.2 Regional Market Shares, 2023
      • 14.8.3.3 Business Segment Market Shares, 2023
    • 14.8.4 Service Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 Boehringer Ingelheim International GmbH
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
      • 14.9.3.1 Net Revenue, 2018-2023
      • 14.9.3.2 Regional Market Shares, 2023
      • 14.9.3.3 Business Segment Market Shares, 2023
    • 14.9.4 Service Benchmarking
  • 14.10 Piramal Pharma Solutions
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Service Benchmarking
    • 14.10.4 Strategic Outlook
  • 14.11 Samsung Biologics
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2018-2023
    • 14.11.4 Service Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 WuXi AppTec
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2018-2023
      • 14.12.3.2 Regional Market Shares, 2023
      • 14.12.3.3 Business Segment Market Shares, 2023
    • 14.12.4 Service Benchmarking
    • 14.12.5 Strategic Outlook
  • 14.13 FUJIFILM Diosynth Biotechnologies
    • 14.13.1 Company Snapshot
    • 14.13.2 Company Overview
    • 14.13.3 Financial Analysis
      • 14.13.3.1 Net Revenue, 2018-2023
      • 14.13.3.2 R&D, 2018-2023
    • 14.13.4 Service Benchmarking
    • 14.13.5 Strategic Outlook
  • 14.14 ICON plc
    • 14.14.1 Company Snapshot
    • 14.14.2 Company Overview
    • 14.14.3 Financial Analysis
      • 14.14.3.1 Net Revenue, 2018-2023
      • 14.14.3.2 Regional Market Shares, 2023
    • 14.14.4 Service Benchmarking
    • 14.14.5 Strategic Outlook
  • 14.15 Abnova Corporation
    • 14.15.1 Company Snapshot
    • 14.15.2 Company Overview
    • 14.15.3 Service Benchmarking
    • 14.15.4 Strategic Outlook
  • 14.16 Vetter Pharma
    • 14.16.1 Company Snapshot
    • 14.16.2 Company Overview
    • 14.16.3 Service Benchmarking
    • 14.16.4 Strategic Outlook
  • 14.17 Aenova Group
    • 14.17.1 Company Snapshot
    • 14.17.2 Company Overview
    • 14.17.3 Financial Analysis
      • 14.17.3.1 Net Revenue, 2018-2022
      • 14.17.3.2 Regional Market Shares, 2022
      • 14.17.3.3 Business Segment Market Shares, 2022
    • 14.17.4 Service Benchmarking
    • 14.17.5 Strategic Outlook
  • 14.18 Almac Group
    • 14.18.1 Company Snapshot
    • 14.18.2 Company Overview
    • 14.18.3 Service Benchmarking
    • 14.18.4 Strategic Outlook
  • 14.19 Nipro Pharma Corporation
    • 14.19.1 Company Snapshot
    • 14.19.2 Company Overview
    • 14.19.3 Financial Analysis
      • 14.19.3.1 Net Revenue, 2018-2023
      • 14.19.3.2 R&D, 2018-2023
      • 14.19.3.3 Regional Market Shares, 2023
      • 14.19.3.4 Business Segment Market Shares, 2023
    • 14.19.4 Service Benchmarking
    • 14.19.5 Strategic Outlook
  • 14.20 Jubilant Pharmova Limited
    • 14.20.1 Company Snapshot
    • 14.20.2 Company Overview
    • 14.20.3 Service Benchmarking
    • 14.20.4 Strategic Outlook
  • 14.21 Pfizer Inc.
    • 14.21.1 Company Snapshot
    • 14.21.2 Company Overview
    • 14.21.3 Financial Analysis
      • 14.21.3.1 Net Revenue, 2018-2023
      • 14.21.3.2 R&D, 2018-2023
      • 14.21.3.3 Regional Market Shares, 2023
      • 14.21.3.4 Business Segment Market Shares, 2023
    • 14.21.4 Service Benchmarking
    • 14.21.5 Strategic Outlook
  • 14.22 Grifols, S.A.
    • 14.22.1 Company Snapshot
    • 14.22.2 Company Overview
    • 14.22.3 Financial Analysis
      • 14.22.3.1 Net Revenue, 2018-2023
      • 14.22.3.2 R&D, 2018-2023
    • 14.22.4 Strategic Outlook
  • 14.23 Charles River Laboratories
    • 14.23.1 Company Snapshot
    • 14.23.2 Company Overview
    • 14.23.3 Financial Analysis
      • 14.23.3.1 Net Revenue, 2018-2023
      • 14.23.3.2 Regional Market Shares, 2023
      • 14.23.3.3 Business Segment Market Shares, 2023
    • 14.23.4 Service Benchmarking
    • 14.23.5 Strategic Outlook
  • 14.24 IQVIA Inc.
    • 14.24.1 Company Snapshot
    • 14.24.2 Company Overview
    • 14.24.3 Financial Analysis
      • 14.24.3.1 Net Revenue, 2018-2023
      • 14.24.3.2 Regional Market Shares, 2023
      • 14.24.3.3 Business Segment Market Shares, 2023
    • 14.24.4 Service Benchmarking
    • 14.24.5 Strategic Outlook
  • 14.25 Baxter
    • 14.25.1 Company Snapshot
    • 14.25.2 Company Overview
    • 14.25.3 Financial Analysis
      • 14.25.3.1 Net Revenue, 2018-2023
      • 14.25.3.2 R&D, 2018-2023
      • 14.25.3.3 Regional Market Shares, 2023
      • 14.25.3.4 Business Segment Market Shares, 2023
    • 14.25.4 Service Benchmarking
  • 14.26 Curia Global, Inc.
    • 14.26.1 Company Snapshot
    • 14.26.2 Company Overview
    • 14.26.3 Service Benchmarking
    • 14.26.4 Strategic Outlook
  • 14.27 Lannett
    • 14.27.1 Company Snapshot
    • 14.27.2 Company Overview
    • 14.27.3 Service Benchmarking

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players

List of Tables

  • Table 1 Pharmaceutical Contract Manufacturing Market Snapshot, 2024 & 2034 (US$ million, CAGR %)
  • Table 2 Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 3 Pharmaceutical Manufacturing Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 4 Pharmaceutical Manufacturing Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 5 Drug Development Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 6 Drug Development Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 7 Biologics Manufacturing Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 8 Biologics Manufacturing Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 9 Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 10 Branded Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 11 Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 12 Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 13 Big Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 14 Small & Medium-sized Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 15 Generic Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 16 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 17 Pharmaceutical Contract Manufacturing Market Forecast by Pharmaceutical Manufacturing Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 18 Clinical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 19 Commercial Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 20 Pharmaceutical Contract Manufacturing Market Forecast by Region, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 21 North America Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 22 North America Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 23 North America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 24 North America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 25 North America Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 26 U.S. Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 27 Canada Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 28 Europe Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 29 Europe Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 30 Europe Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 31 Europe Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 32 Europe Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 33 Germany Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 34 UK Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 35 France Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 36 Italy Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 37 Spain Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 38 Russia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 39 Switzerland Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 40 Netherlands Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 41 Rest of Europe Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 42 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 43 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 44 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 45 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 46 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 47 Japan Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 48 China Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 49 India Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 50 Australia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 51 Australia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 52 Malaysia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 53 Singapore Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 54 Indonesia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 55 Rest of Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 56 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 57 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 58 Latin America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 59 Latin America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 60 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 61 Brazil Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 62 Mexico Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 63 Argentina Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 64 Colombia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 65 Rest of Latin America Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 66 MEA Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 67 MEA Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 68 MEA Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 69 MEA Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 70 MEA Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %, CAGR %)
  • Table 71 GCC Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 72 South Africa Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 73 Rest of MEA Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Bn, AGR %, CAGR %)
  • Table 74 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 75 Lonza: Service Benchmarking
  • Table 76 Lonza: Strategic Outlook
  • Table 77 Catalent, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 78 Catalent, Inc.: Service Benchmarking
  • Table 79 Catalent, Inc.: Strategic Outlook
  • Table 80 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Recipharm AB: Service Benchmarking
  • Table 82 Recipharm AB: Strategic Outlook
  • Table 83 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 AbbVie Inc.: Service Benchmarking
  • Table 85 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Thermo Fisher Scientific Inc.: Service Benchmarking
  • Table 87 Thermo Fisher Scientific Inc.: Strategic Outlook
  • Table 88 Siegfried Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Siegfried Holding AG: Service Benchmarking
  • Table 90 Siegfried Holding AG: Strategic Outlook
  • Table 91 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Evonik Industries AG: Service Benchmarking
  • Table 93 Evonik Industries AG: Strategic Outlook
  • Table 94 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 Boehringer Ingelheim International GmbH: Service Benchmarking
  • Table 96 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Piramal Pharma Solutions: Service Benchmarking
  • Table 98 Piramal Pharma Solutions: Strategic Outlook
  • Table 99 Samsung Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Samsung Biologics: Service Benchmarking
  • Table 101 Samsung Biologics: Strategic Outlook
  • Table 102 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 WuXi AppTec: Service Benchmarking
  • Table 104 WuXi AppTec: Strategic Outlook
  • Table 105 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 FUJIFILM Diosynth Biotechnologies: Service Benchmarking
  • Table 107 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
  • Table 108 ICON plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 ICON plc: Service Benchmarking
  • Table 110 ICON plc: Strategic Outlook
  • Table 111 Abnova Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 112 Abnova Corporation: Service Benchmarking
  • Table 113 Abnova Corporation: Strategic Outlook
  • Table 114 Vetter Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Vetter Pharma: Service Benchmarking
  • Table 116 Vetter Pharma: Strategic Outlook
  • Table 117 Aenova Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Aenova Group: Service Benchmarking
  • Table 119 Aenova Group: Strategic Outlook
  • Table 120 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Almac Group: Service Benchmarking
  • Table 122 Almac Group: Strategic Outlook
  • Table 123 Nipro Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Nipro Pharma Corporation: Service Benchmarking
  • Table 125 Nipro Pharma Corporation: Strategic Outlook
  • Table 126 Jubilant Pharmova Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Jubilant Pharmova Limited: Service Benchmarking
  • Table 128 Jubilant Pharmova Limited: Strategic Outlook
  • Table 129 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Pfizer Inc.: Service Benchmarking
  • Table 131 Pfizer Inc.: Strategic Outlook
  • Table 132 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Grifols, S.A.: Strategic Outlook
  • Table 134 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 135 Charles River Laboratories: Service Benchmarking
  • Table 136 Charles River Laboratories: Strategic Outlook
  • Table 137 IQVIA Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 138 IQVIA Inc.: Service Benchmarking
  • Table 139 IQVIA Inc.: Strategic Outlook
  • Table 140 Baxter: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 141 Baxter: Service Benchmarking
  • Table 142 Curia Global, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Curia Global, Inc.: Service Benchmarking
  • Table 144 Curia Global, Inc.: Strategic Outlook
  • Table 145 Lannett: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Lannett: Service Benchmarking
  • List of Figures
  • Figure 1 Pharmaceutical Contract Manufacturing Market Segmentation
  • Figure 2 Pharmaceutical Contract Manufacturing Market by Services: Market Attractiveness Index
  • Figure 3 Pharmaceutical Contract Manufacturing Market by Drug Type: Market Attractiveness Index
  • Figure 4 Pharmaceutical Contract Manufacturing Market by End-users: Market Attractiveness Index
  • Figure 5 Pharmaceutical Contract Manufacturing Market by Scale of Operation: Market Attractiveness Index
  • Figure 6 Pharmaceutical Contract Manufacturing Market Attractiveness Index by Region
  • Figure 7 Pharmaceutical Contract Manufacturing Market: Market Dynamics
  • Figure 8 Pharmaceutical Contract Manufacturing Market: Impact Analysis
  • Figure 9 Pharmaceutical Contract Manufacturing Market: Porter's Five Forces Analysis
  • Figure 10 Pharmaceutical Contract Manufacturing Market: PEST Analysis
  • Figure 11 Pharmaceutical Contract Manufacturing Market: SWOT Analysis
  • Figure 12 Pharmaceutical Contract Manufacturing Market Attractiveness Index by Services
  • Figure 13 Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 14 Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024, 2029, 2034 (%)
  • Figure 15 Pharmaceutical Manufacturing Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 16 Pharmaceutical Manufacturing Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 17 Pharmaceutical Manufacturing Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 18 Drug Development Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 19 Drug Development Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 20 Drug Development Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 21 Biologics Manufacturing Services Segment Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 22 Biologics Manufacturing Services Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 23 Biologics Manufacturing Services Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 24 Pharmaceutical Contract Manufacturing Market Attractiveness Index by Services
  • Figure 25 Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 26 Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024, 2029, 2034 (%)
  • Figure 27 Branded Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 28 Branded Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 29 Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 30 Generics Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 31 Pharmaceutical Contract Manufacturing Market Attractiveness Index by End-users
  • Figure 32 Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 33 Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024, 2029, 2034 (%)
  • Figure 34 Big Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 35 Big Pharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 36 Small & Medium-sized Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 37 Small & Medium-sized Pharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 38 Generic Pharmaceutical Companies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 39 Generic Pharmaceutical Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 40 Other End-users Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 41 Other End-users Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 42 Pharmaceutical Contract Manufacturing Market Attractiveness Index by Scale of Operation
  • Figure 43 Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 44 Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024, 2029, 2034 (%)
  • Figure 45 Clinical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 46 Clinical Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 47 Commercial Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
  • Figure 48 Commercial Segment Market Share Forecast by Region, 2024 & 2034 (%)
  • Figure 49 Pharmaceutical Contract Manufacturing Market Forecast by Region 2024, 2029, 2034 (Revenue, CAGR%)
  • Figure 50 Pharmaceutical Contract Manufacturing Market Share Forecast by Region 2024, 2029, 2034 (%)
  • Figure 51 Pharmaceutical Contract Manufacturing Market by Region, 2024-2034 (US$ Bn, AGR %)
  • Figure 52 North America Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • Figure 53 North America Pharmaceutical Contract Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 54 North America Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 55 North America Pharmaceutical Contract Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 56 North America Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 57 North America Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024 & 2034 (%)
  • Figure 58 North America Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 59 North America Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 60 North America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 61 North America Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 62 North America Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 63 North America Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024 & 2034 (%)
  • Figure 64 U.S. Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 65 Canada Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 66 Europe Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • Figure 67 Europe Pharmaceutical Contract Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 68 Europe Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 69 Europe Pharmaceutical Contract Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 70 Europe Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 71 Europe Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024 & 2034 (%)
  • Figure 72 Europe Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 73 Europe Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 74 Europe Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 75 Europe Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 76 Europe Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 77 Europe Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024 & 2034 (%)
  • Figure 78 Germany Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 79 UK Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 80 France Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 81 Italy Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 82 Spain Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 83 Russia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 84 Switzerland Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 85 Netherlands Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 86 Rest of Europe Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 87 Asia Pacific Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • Figure 88 Asia Pacific Pharmaceutical Contract Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 89 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 90 Asia Pacific Pharmaceutical Contract Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 91 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 92 Asia Pacific Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024 & 2034 (%)
  • Figure 93 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 94 Asia Pacific Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 95 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 96 Asia Pacific Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 97 Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 98 Asia Pacific Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024 & 2034 (%)
  • Figure 99 Japan Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 100 China Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 101 India Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 102 Australia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 103 South Korea Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 104 Malaysia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 105 Singapore Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 106 Indonesia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 107 Rest of Asia Pacific Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 108 Latin America Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • Figure 109 Latin America Pharmaceutical Contract Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 110 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 111 Latin America Pharmaceutical Contract Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 112 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 113 Latin America Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024 & 2034 (%)
  • Figure 114 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 115 Latin America Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 116 Latin America Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 117 Latin America Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 118 Latin America Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 119 Latin America Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024 & 2034 (%)
  • Figure 120 Brazil Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 121 Mexico Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 122 Argentina Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 123 Colombia Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 124 Rest of Latin America Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 125 MEA Pharmaceutical Contract Manufacturing Market Attractiveness Index
  • Figure 126 MEA Pharmaceutical Contract Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Billion)
  • Figure 127 MEA Pharmaceutical Contract Manufacturing Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
  • Figure 128 MEA Pharmaceutical Contract Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
  • Figure 129 MEA Pharmaceutical Contract Manufacturing Market Forecast by Services, 2024-2034 (US$ Billion, AGR %)
  • Figure 130 MEA Pharmaceutical Contract Manufacturing Market Share Forecast by Services, 2024 & 2034 (%)
  • Figure 131 MEA Pharmaceutical Contract Manufacturing Market Forecast by Drug Type, 2024-2034 (US$ Billion, AGR %)
  • Figure 132 MEA Pharmaceutical Contract Manufacturing Market Share Forecast by Drug Type, 2024 & 2034 (%)
  • Figure 133 MEA Pharmaceutical Contract Manufacturing Market Forecast by End-users, 2024-2034 (US$ Billion, AGR %)
  • Figure 134 MEA Pharmaceutical Contract Manufacturing Market Share Forecast by End-users, 2024 & 2034 (%)
  • Figure 135 MEA Pharmaceutical Contract Manufacturing Market Forecast by Scale of Operation, 2024-2034 (US$ Billion, AGR %)
  • Figure 136 MEA Pharmaceutical Contract Manufacturing Market Share Forecast by Scale of Operation, 2024 & 2034 (%)
  • Figure 137 GCC Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 138 South Africa Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 139 Rest of MEA Pharmaceutical Contract Manufacturing Market Forecast, 2024-2034 (US$ Billion, AGR %)
  • Figure 140 Lonza: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 141 Lonza: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 142 Lonza: Regional Market Shares (%), 2023
  • Figure 143 Lonza: Business Segment Market Shares (%), 2023
  • Figure 144 Lonza: SWOT Analysis
  • Figure 145 Catalent, Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 146 Catalent, Inc.: Regional Market Shares (%), 2023
  • Figure 147 Catalent, Inc.: Business Segment Market Shares (%), 2023
  • Figure 148 Catalent, Inc.: SWOT Analysis
  • Figure 149 Recipharm AB: SWOT Analysis
  • Figure 150 AbbVie Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 151 AbbVie Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 152 AbbVie Inc.: Regional Market Shares (%), 2023
  • Figure 153 AbbVie Inc.: Business Segment Market Shares (%), 2023
  • Figure 154 AbbVie Inc.: SWOT Analysis
  • Figure 155 Thermo Fisher Scientific Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 156 Thermo Fisher Scientific Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 157 Thermo Fisher Scientific Inc.: Regional Market Shares (%), 2023
  • Figure 158 Thermo Fisher Scientific Inc.: Business Segment Market Shares (%), 2023
  • Figure 159 Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 160 Siegfried Holding AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 161 Siegfried Holding AG: Business Segment Market Shares (%), 2023
  • Figure 162 Evonik Industries AG: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 163 Evonik Industries AG: Regional Market Shares (%), 2023
  • Figure 164 Evonik Industries AG: Business Segment Market Shares (%), 2023
  • Figure 165 Boehringer Ingelheim International GmbH: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 166 Boehringer Ingelheim International GmbH: Regional Market Shares (%), 2023
  • Figure 167 Boehringer Ingelheim International GmbH: Business Segment Market Shares (%), 2023
  • Figure 168 Samsung Biologics: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 169 WuXi AppTec: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 170 WuXi AppTec: Regional Market Shares (%), 2023
  • Figure 171 WuXi AppTec: Business Segment Market Shares (%), 2023
  • Figure 172 FUJIFILM Diosynth Biotechnologies: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 173 FUJIFILM Diosynth Biotechnologies: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 174 ICON plc: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 175 ICON plc: Regional Market Shares (%), 2023
  • Figure 176 Aenova Group: Net Revenue, 2018-2022 (US$ Million, AGR %)
  • Figure 177 Aenova Group: Regional Market Shares (%), 2022
  • Figure 178 Aenova Group: Business Segment Market Shares (%), 2022
  • Figure 179 Nipro Pharma Corporation: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 180 Nipro Pharma Corporation: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 181 Nipro Pharma Corporation: Regional Market Shares (%), 2023
  • Figure 182 Nipro Pharma Corporation: Business Segment Market Shares (%), 2023
  • Figure 183 Pfizer Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 184 Pfizer Inc.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 185 Pfizer Inc.: Regional Market Shares (%), 2023
  • Figure 186 Pfizer Inc.: Business Segment Market Shares (%), 2023
  • Figure 187 Grifols, S.A.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 188 Grifols, S.A.: R&D, 2018-2023 (US$ Million, AGR %)
  • Figure 189 Charles River Laboratories: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 190 Charles River Laboratories: Regional Market Shares (%), 2023
  • Figure 191 Charles River Laboratories: Business Segment Market Shares (%), 2023
  • Figure 192 IQVIA Inc.: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 193 IQVIA Inc.: Regional Market Shares (%), 2023
  • Figure 194 IQVIA Inc.: Business Segment Market Shares (%), 2023
  • Figure 195 Baxter: Net Revenue, 2018-2023 (US$ Million, AGR %)
  • Figure 196 Baxter: R&D, 2018-2023 (US$ Million, AGR %)